Company / R&D Expense
Astria Therapeutics, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$77.1M
FY2024
5-year range
$15.6M / $77.1M
FY2020-FY2024
Trend
+83.0%
vs FY2023
Sector context
#160 of 210
Health Care
What the data says
Astria Therapeutics, Inc.'s r&d expense of $77M is lower than 76% of companies in the Health Care sector (FY2024). R&D Expense has increased for 3 consecutive years, from $16M in FY2021 to $77M in FY2024.
Based on SEC 10-K filings.
$77M in FY2024 with a 5-year CAGR of +33.3%.
Improved from $34M to $77M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +70.5%
- 5-Year CAGR
- +33.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 210This company $77.1M Sector average $644.1M
▼
-88.0% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +33.3%, indicating consistent growth.
- In FY2024, r&d expense increased 83.0% year-over-year.
- Ranks #160 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $77.1M | +83.0% |
| FY2023 | $42.1M | +22.9% |
| FY2022 | $34.3M | +120.3% |
| FY2021 | $15.6M | -39.2% |
| FY2020 | $25.6M | +39.7% |
| FY2019 | $18.3M | +7.5% |
| FY2018 | $17.0M | -8.8% |
| FY2017 | $18.7M | -26.6% |
| FY2016 | $25.4M | +10.5% |
| FY2015 | $23.0M | +46.8% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026